New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney diseaseZHUBEI CITY, Taiwan and RALEIGH, N.C.,...
Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...
STAMFORD, Conn., June 05, 2026 (GLOBE NEWSWIRE) -- Oban BioPharma today announced that preclinical data for OBT-676, a lead small-molecule candidate for the treatment of obesity and type 2 diabetes, has been selected for a late-breaking presentation at the upcoming American Diabetes Association (ADA) 86th Scientific Sessions being held from June 5th-8th in New Orleans, LA. The study characterizes OBT-676 as a new molecular entity that achieves potent full agonism at the amylin and calcitonin receptors (DACRA) while simultaneously delivering partial agonism across the GLP-1, GIP, and glucagon (Triple-G) pathways. OBT-676 demonstrated significant reduction in food intake and adipose-selective weight loss in the industry-standard rat diet-induced obesity (DIO) model.
The First Time a Game in the Legendary Franchise Comes to ConsolesBELLEVUE, Wash., June 6, 2026 /PRNewswire/ -- Critically-acclaimed game development studio ArenaNet® tonight...
The First Time a Game in the Legendary Franchise Comes to ConsolesBELLEVUE, Wash., June 5, 2026 /PRNewswire/ -- Critically-acclaimed game development studio ArenaNet® tonight...
LOUISVILLE, Colo., June 5, 2026 /PRNewswire/ -- FlackTek™, a global leader in high-performance mixing and material processing technology, today announced the appointment of Dustin...
The First Time a Game in the Legendary Franchise Comes to ConsolesBELLEVUE, Wash., June 5, 2026 /CNW/ -- Critically-acclaimed game development studio ArenaNet® tonight announced...
The First Time a Game in the Legendary Franchise Comes to ConsolesBELLEVUE, Wash., June 5, 2026 /PRNewswire/ -- Critically-acclaimed game development studio ArenaNet® tonight announced...
TORTOLA, British Virgin Islands, June 05, 2026 (GLOBE NEWSWIRE) -- Orca Energy Group Inc. (“Orca” or the “Company” and includes its subsidiaries and affiliates) (TSX-V: ORC.A, ORC.B) today announces that it has filed its condensed consolidated interim (unaudited) financial statements and management’s discussion and analysis for the three month period ended March 31, 2026 (“Q1 2026”) with the Canadian securities regulatory authorities. All amounts are in United States dollars (“$”) unless otherwise stated.